...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

NovImmune Initiates a Proof-of-Concept Study in Primary Biliary Cirrhosis (PBC)

| Print |
Thursday, 22 September 2011 09:30 (UTC + 2)

NovImmune_Logo

The PIANO study: Primary biliary cirrhosis: Investigating A New treatment Option using NI-0801, a fully human anti-CXCL10 monoclonal antibody 

Plan-Les-Ouates, Geneva, Switzerland, September 22, 2011 / B3C newswire / - NovImmune announced today that a Proof-of–Concept (PoC) study with NI-0801, a fully human monoclonal antibody neutralizing the CXCL10/Interferon-gamma-inducible protein-10 (IP-10) chemokine, was initiated in patients with PBC. This is a chronic inflammatory, debilitating condition of the bile ducts that leads to liver cirrhosis and eventually to liver failure, and which represents a high unmet medical need. Preclinical models and human data strongly associate CXCL10/IP-10 to the etiology of PBC. Two previous Phase I trials in healthy volunteers have demonstrated that the administration of NI-0801 is safe and well tolerated.

PBC is an orphan, autoimmune, progressive liver disorder that primarily affects females. Typically, the disease becomes apparent during middle age (between 30 and 65). Inflammation, developing around the small bile ducts, progressively induces an obstruction and accumulation of bile leading to damage of liver cells. As damage worsens, scarring (cirrhosis) gradually occurs and may ultimately cause liver failure, for which transplantation is the only therapeutic option. Common early symptoms of PBC are itching and fatigue. Currently, only symptomatic treatments are available and the need for disease modifier drugs is extremely high.

CXCL10/IP-10 is secreted by several cell types in response to inflammation and contributes significantly to the entry of immune cells into the liver. These cells are responsible for the destruction of the biliary tract in PBC and, with time, provoke the dysregulated scarring process which characterizes the late stages of the disease. The neutralization of CXCL10/IP-10 with NI-0801 offers the possibility to interfere with one of the key inflammatory processes that leads to PBC.

David Adams, Professor of Hepatology, Director of the NIHR BRU Centre for Liver Research at the University of Birmingham, and Principal Investigator of the PoC study, commented that ”the therapeutic approach of neutralizing CXCL10/IP-10 with NI-0801 will potentially offer for the first time great benefits to the large and therapeutically ill-served PBC patient population”.


About PBC, an orphan disease
An orphan disease is any disease that affects a small percentage of the population. PBC affects approx. 4 in 10’000 people and therefore is considered as an Orphan disease. Worldwide approx. 300’000 people suffer from this disease.

About NovImmune SA
NovImmune SA (‘NovImmune’) is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders. NovImmune has generated to date seven proprietary mAbs. The pipeline is a balance of preclinical and clinical compounds with a mix of both clinically validated as well as novel targets. Each of these portfolio products has the potential to become a medicine for multiple medical conditions due to the overlapping mechanism of action underlying these types of diseases. Four compounds are at this time in clinical development, with the most advanced in Phase II.

In addition, NovImmune has developed a proprietary platform for the generation of fully human mono-, bi-- and panspecific antibodies.


Contact

Jack Barbut
CEO
NovImmune SA
14 ch. des Aulx
1228 Plan-Les-Ouates, Geneva
Switzerland

T +41 22 839 71 41
F +41 22 839 71 43


Luca Bolliger
Director, Business Development
NovImmune SA
14 ch. des Aulx
1228 Plan-Les-Ouates, Geneva
Switzerland

T +41 22 593 51 15
F +41 22 839 71 43